Darbepoetin alfa in the treatment of anemia in renal transplant patients: A single-center report [8]

Transplantation

Volumn 77, Issue 12, 2004, Pages 1914-1915

  El Haggan, Wael ^a,b   Vallet, Lydie ^a   De Ligny, Bruno Hurault ^a   Pujo, Myriam ^a   Corne, Bénédicte ^a   Lobbedez, Thierry ^a   Levaltier, Béatrice ^a   Ryckelynck, Jean Philippe ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b CHU Clemenceau   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CREATININE; FERRITIN; HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; BLOOD PRESSURE; CLINICAL ARTICLE; CREATININE CLEARANCE; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; ORGAN TRANSPLANTATION; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; TREATMENT OUTCOME;

ANEMIA; BIOLOGICAL MARKERS; BLOOD CELL COUNT; BLOOD PRESSURE; CREATININE; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROTEINURIA;

EID: 3042569733     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000131477.56153.05     Document Type: Letter

References (7)

1. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 2000; 11: S1.
2. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16: S14.
3. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741.
4. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anemia associated with cancer chemotherapy. Br J Cancer 2002; 87: 268.
5. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
6. Vanrenterghem Y, Vanwalleghem J. Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13: 13.
7. Yorgin PD, Scandling JD, Belson A, et al. Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem? Am J Transplant 2002; 2: 429.